Which medication, ropinirole or pramipexole, is more appropriate for treating restless‑legs syndrome in children?

Neither Ropinirole nor Pramipexole Should Be Used as Standard Treatment for RLS in Children

The most recent 2025 AASM guidelines do not recommend either ropinirole or pramipexole for pediatric RLS—in fact, these dopamine agonists are explicitly recommended against even in adults, and no pediatric-specific recommendations exist for these agents. 1

The Evidence-Based Approach for Pediatric RLS

First-Line Treatment: Iron Supplementation

For children with RLS, ferrous sulfate is the only pharmacological intervention with guideline support (conditional recommendation, very low certainty of evidence). 1 This should be prescribed when iron parameters are appropriate—though the guidelines reference specific iron parameters in a "good practice statement" not fully detailed in the provided evidence.

Why Dopamine Agonists Are Problematic

The 2025 AASM guidelines represent a significant shift from previous practice, now suggesting against the standard use of both pramipexole and ropinirole even in adults (conditional recommendations, moderate certainty of evidence for both). 1

Key concerns include:

• Augmentation risk: Both agents cause worsening of RLS symptoms with long-term use, particularly problematic in the pediatric population who would require decades of treatment
• The guidelines note these may only be considered in adults "who place a higher value on reduction of restless legs symptoms with short-term use and a lower value on adverse effects with long-term use (particularly augmentation)" 1
• This risk-benefit calculation becomes even more unfavorable in children

The Guideline Gap for Pediatric RLS

Critically, the 2025 AASM guidelines provide only one recommendation specific to children with RLS—the use of ferrous sulfate. 1 The absence of any pediatric recommendations for dopamine agonists, despite their inclusion in adult recommendations (albeit negative ones), strongly suggests these agents should be avoided in children.

If You Must Compare Them (Though You Shouldn't Use Either)

The research evidence comparing these agents in adults shows:

• Pramipexole may have slight advantages over ropinirole in terms of efficacy (greater IRLS score reduction) and tolerability (lower incidence of nausea, vomiting, and dizziness) based on indirect meta-analysis 2
• However, a direct polysomnographic comparison found no significant differences between the two agents 3
• Ropinirole carries higher nausea risk and more discontinuations due to lack of efficacy compared to pramipexole 4

Clinical Algorithm for Pediatric RLS

1. Confirm diagnosis carefully: Growing pains, leg cramps, and behavioral issues are common mimics in children 1
2. Check iron parameters: Ferritin and transferrin saturation
3. Prescribe ferrous sulfate with vitamin C if iron parameters indicate deficiency
4. Avoid dopamine agonists as standard practice given augmentation risks and lack of pediatric evidence
5. If symptoms persist despite iron repletion: Consider referral to pediatric sleep specialist for alternative approaches, as evidence for other pharmacological options in children is essentially non-existent

Critical Caveat

The FDA labels for both ropinirole 5 indicate approval for RLS treatment but do not specify pediatric dosing or safety data, further supporting the position that these agents lack adequate evidence for use in children.

Bottom line: Neither agent is appropriate for standard pediatric RLS treatment. Use ferrous sulfate as first-line therapy. 1